Exploring the immunomodulatory role of virtual memory CD8+ T cells: Role of IFN gamma in tumor growth control
Constanza Savid-Frontera, María Estefania Viano, Natalia Soledad Baez, Nicolás Leonel Lidon, Quentin Fontaine, Howard A. Young, Lene Vimeux, Emmanuel Donnadieu, María Cecilia Rodriguez‐Galán
Abstract
Virtual memory CD8 + T cells (T VM ) have been described as cells with a memory-like phenotype but without previous antigen (Ag) exposure. T VM cells have the ability to respond better to innate stimuli rather than by TCR engagement, producing large amounts of interferon gamma (IFNγ) after stimulation with interleukin (IL)-12 plus IL-18. As a result of the phenotypic similarity, T VM cells have been erroneously included in the central memory T cell subset for many years. However, they can now be discriminated via the CD49d receptor, which is up-regulated only on conventional memory T cells (T MEM ) and effector T cells (T EFF ) after specific cognate Ag recognition by a TCR. In this work we show that systemic expression of IL-12 plus IL-18 induced an alteration in the normal T VM vs T MEM /T EFF distribution in secondary lymphoid organs and a preferential enrichment of T VM cells in the melanoma (B16) and the pancreatic ductal adenocarcinoma (KPC) tumor models. Using our KPC bearing OT-I mouse model, we observed a significant increase in CD8 + T cell infiltrating the tumor islets after IL-12+IL-18 stimulation with a lower average speed when compared to those from control mice. This finding indicates a stronger interaction of T cells with tumor cells after cytokine stimulation. These results correlate with a significant reduction in tumor size in both tumor models in IL-12+IL-18-treated OT-I mice compared to control OT-I mice. Interestingly, the absence of IFNγ completely abolished the high antitumor capacity induced by IL-12+IL-18 expression, indicating an important role for these cytokines in early tumor growth control. Thus, our studies provide significant new information that indicates an important role of T VM cells in the immune response against cancer.